A Real-world, Multi-center, Prospective, Observational Study for PNH in China

Active, not recruitingOBSERVATIONAL
Enrollment

724

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Trial Locations (40)

100000

Research Site, Beijing

100044

Research Site, Beijing

110001

Research Site, Shenyang

130021

Research Site, Changchun

150001

Research Site, Harbin

200040

Research Site, Shanghai

200336

Research Site, Shanghai

210029

Research Site, Nanjing

221002

Research Site, Xuzhou

226001

Research Site, Nantong

230002

Research Site, Hefei

250000

Research Site, Jinan

255090

Research Site, Zibo

266000

Research Site, Qingdao

276034

Research Site, Linyi

300020

Research Site, Tianjin

300052

Research Site, Tianjin

300190

Research Site, Tianjin

330006

Research Site, Nanchang

330008

Research Site, Nanchang

410005

Research Site, Changsha

410008

Research Site, Changsha

430000

Research Site, Wuhan

430030

Research Site, Wuhan

450003

Research Site, Zhengzhou

450052

Research Site, Zhengzhou

463599

Research Site, Zhengzhou

510080

Research Site, Guangzhou

510180

Research Site, Guangzhou

510515

Research Site, Guangzhou

530021

Research Site, Nanning

550004

Research Site, Guiyang

610041

Research Site, Chengdu

610072

Research Site, Chengdu

650034

Research Site, Kunming

710061

Research Site, Xi’an

710068

Research Site, Xi’an

050000

Research Site, Shijiazhuang

030000

Research Site, Taiyuan

Unknown

Research Site, Hangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY